Showing results (131-140 of 162) with videos related to
Sort By:
Pageof 17
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.Journal of Hepatology|July 26, 2011
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 studyJean-Pierre Zarski, Nathalie Sturm, Jérôme Guechot, et al.Clinics and Research in Hepatology and Gastroenterology|February 26, 2021
Covid-19 in liver transplant recipients: the French SOT COVID registryJérôme Dumortier, Christophe Duvoux, Olivier Roux, et al.Viruses|January 21, 2023
Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?Lucy Meunier, Mohamed Belkacemi, George Philippe Pageaux, et al.BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.Journal of Hepatology|July 13, 2025
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trialThierry Thévenot, Laure Elkrief, Christophe Bureau, et al.Frontiers in Immunology|January 25, 2024
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.The New England Journal of Medicine|June 7, 2018
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary CholangitisChristophe Corpechot, Olivier Chazouillères, Alexandra Rousseau, et al.Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.Pageof 17